Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLM-102 in Relapsed and Refractory Acute Myeloid Leukemia
NCT07549464Phase 1Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PLM-102 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Adverse Events at 1 year, Dose Limiting Toxicities and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PLM-102
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07549464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549464.